A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD

INTRODUCTION: Tolvaptan, for treatment of autosomal dominant polycystic kidney disease (ADPKD), is provided as immediate-release (IR) tablets administered twice daily in split-dose regimens to suppress urine osmolality to <300 mOsm/kg. A modified-release (MR) formulation was developed for once-da...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrone, Ronald D., Chapman, Arlene B., Oberdhan, Dorothee, Czerwiec, Frank S., Sergeyeva, Olga, Ouyang, John, Shoaf, Susan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271942/
https://www.ncbi.nlm.nih.gov/pubmed/32518861
http://dx.doi.org/10.1016/j.ekir.2020.03.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271942/
https://www.ncbi.nlm.nih.gov/pubmed/32518861
http://dx.doi.org/10.1016/j.ekir.2020.03.013

Ejemplares similares